MX2019001795A - Anticuerpo específico contra e. coli mdr. - Google Patents

Anticuerpo específico contra e. coli mdr.

Info

Publication number
MX2019001795A
MX2019001795A MX2019001795A MX2019001795A MX2019001795A MX 2019001795 A MX2019001795 A MX 2019001795A MX 2019001795 A MX2019001795 A MX 2019001795A MX 2019001795 A MX2019001795 A MX 2019001795A MX 2019001795 A MX2019001795 A MX 2019001795A
Authority
MX
Mexico
Prior art keywords
antibody
mdr
specific antibody
isolated
coli specific
Prior art date
Application number
MX2019001795A
Other languages
English (en)
Inventor
Eszter Nagy
Valéria Szijárto
Zoltán Magyarics
Irina Mirkina
Gerhild Zauner
Jolanta Lukasiewicz
Adriana Badarau
Gábor Nagy
Luis Guachalla
Original Assignee
X4 Pharmaceuticals Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Austria Gmbh filed Critical X4 Pharmaceuticals Austria Gmbh
Publication of MX2019001795A publication Critical patent/MX2019001795A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245—Escherichia (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)

Abstract

La presente invención se refiere a un anticuerpo aislado que se une específicamente al antígeno O25b de cepas de E. coli resistentes a múltiples fármacos (MDR), su uso médido y di diagnóstico, el método de producción del anticuerpo, incluyendo una secuencia de nucleótidos aislada, plásmidos y células huésped como se utiliza en la producción del anticuerpo; y adicionalmente un epítopo aislado reconocido por el anticuerpo específico.
MX2019001795A 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr. MX2019001795A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151627 2013-01-17
PCT/EP2014/050895 WO2014111516A1 (en) 2013-01-17 2014-01-17 Mdr e. coli specific antibody

Publications (1)

Publication Number Publication Date
MX2019001795A true MX2019001795A (es) 2022-07-26

Family

ID=47552912

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008653A MX365331B (es) 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr.
MX2019001795A MX2019001795A (es) 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015008653A MX365331B (es) 2013-01-17 2014-01-17 Anticuerpo específico contra e. coli mdr.

Country Status (19)

Country Link
US (5) US9849169B2 (es)
EP (2) EP3167903B1 (es)
JP (3) JP6553517B2 (es)
CN (1) CN105120896B (es)
AU (2) AU2014206799B9 (es)
BR (1) BR112015014991B1 (es)
CA (1) CA2895327C (es)
DK (1) DK2945651T3 (es)
ES (2) ES2718051T3 (es)
HU (1) HUE038915T2 (es)
IL (2) IL273685B2 (es)
MX (2) MX365331B (es)
NZ (1) NZ707777A (es)
PL (1) PL2945651T3 (es)
PT (1) PT2945651T (es)
RU (1) RU2711512C2 (es)
TR (1) TR201807924T4 (es)
WO (1) WO2014111516A1 (es)
ZA (1) ZA201503282B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130323729A1 (en) * 2010-10-29 2013-12-05 Olink Ab Proximity Ligation Technology for Western Blot Applications
IL273685B2 (en) 2013-01-17 2023-10-01 X4 Pharmaceuticals Austria Gmbh Immunogens and vaccines containing O25b antigens
CN113388032A (zh) * 2014-02-06 2021-09-14 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
CN113924112A (zh) 2019-03-18 2022-01-11 杨森制药公司 大肠杆菌o-抗原多糖的生物缀合物、其生产方法及其使用方法
HUE063875T2 (hu) 2019-03-18 2024-02-28 Janssen Pharmaceuticals Inc Eljárások E. coli O-antigén poliszacharidok biokonjugátumainak elõállítására, ezek készítményei és felhasználásuk módszerei

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700612A (en) 1971-06-23 1972-10-24 Tenneco Chem Aqueous surface-coating compositions containing hydroxyalkyl ethers of galactomannan gums as thickeners
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422653D0 (en) * 1984-09-07 1984-10-10 Technology Licence Co Ltd Monoclonal antibodies
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
AUPM399594A0 (en) * 1994-02-21 1994-03-17 Csl Limited Antigenic preparation for treatment or prevention of helicobacter infection
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2406229C (en) 2000-04-18 2010-09-07 Endobiologics, Incorporated Anti-sepsis conjugate vaccine
RU2189253C1 (ru) * 2001-04-09 2002-09-20 Государственный научный центр прикладной микробиологии Диагностикум для идентификации escherichia coli o157 : h7 и способ его получения
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
PT1481057E (pt) 2002-03-07 2006-05-31 Eidgenoess Tech Hochschule Sistema e metodo para a producao de proteinas glicosiladas recombinantes num hospedeiro procariota
AU2003901008A0 (en) 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
ATE430763T1 (de) 2004-03-30 2009-05-15 Nsgene As Therapeutische verwendung des wachstumsfaktors nsg33
CN103396478B (zh) 2005-05-11 2016-09-28 Eth苏黎世公司 来自原核细胞的重组n-糖基化蛋白
ES2388556T3 (es) 2006-03-23 2012-10-16 Novartis Ag Compuestos inmunopotenciadores
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
JP4791866B2 (ja) * 2006-03-24 2011-10-12 国立大学法人秋田大学 下痢原性大腸菌感染症の判別に用いられる固相等
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
LT2257307T (lt) 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
EA024697B1 (ru) * 2009-04-27 2016-10-31 Иммурон Лимитед Применение композиции, содержащей обогащенный анти-lps-антителами иммуноглобулиновый препарат, для лечения заболеваний печени
JP5968784B2 (ja) 2009-11-19 2016-08-10 グリコヴァキシン アーゲー 原核細胞における免疫原性多糖体生成の生合成システム
EP2593594B1 (en) 2010-07-16 2017-09-27 Adimab, LLC Antibody libraries
CN103391714A (zh) 2010-12-10 2013-11-13 默沙东公司 减轻搅动引起的免疫原性组合物聚集的新制剂
WO2013034664A1 (en) 2011-09-06 2013-03-14 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
US9932598B2 (en) 2012-08-02 2018-04-03 The Regents Of The University Of California Metabolic engineering of microbial organisms
EP2892566A1 (en) 2012-09-10 2015-07-15 Glycovaxyn AG Bioconjugates comprising modified antigens and uses thereof
WO2014057109A1 (en) 2012-10-12 2014-04-17 Glycovaxyn Ag Methods of host cell modification
JP2016501550A (ja) 2012-12-27 2016-01-21 グリコヴァキシン アーゲー Ｃｒｍ１９７に関する方法及び組成物
IL273685B2 (en) 2013-01-17 2023-10-01 X4 Pharmaceuticals Austria Gmbh Immunogens and vaccines containing O25b antigens
US11220676B2 (en) 2013-10-11 2022-01-11 Glaxosmithkline Biological Sa Methods of host cell modification
CN113388032A (zh) 2014-02-06 2021-09-14 X4制药(奥地利)有限责任公司 大肠杆菌特异性抗体序列
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
SI3240895T1 (sl) 2014-12-30 2022-04-29 Glaxosmithkline Biologicals S.A. Sestavki in postopki za glikozilacijo proteinov
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
CN113924112A (zh) 2019-03-18 2022-01-11 杨森制药公司 大肠杆菌o-抗原多糖的生物缀合物、其生产方法及其使用方法
HUE063875T2 (hu) 2019-03-18 2024-02-28 Janssen Pharmaceuticals Inc Eljárások E. coli O-antigén poliszacharidok biokonjugátumainak elõállítására, ezek készítményei és felhasználásuk módszerei
FR3098334B1 (fr) 2019-07-05 2021-07-23 Airbus Operations Sas Procédé et système de surveillance d’un état de conscience d’un opérateur dans un poste de pilotage d’un aéronef

Also Published As

Publication number Publication date
JP6643454B2 (ja) 2020-02-12
RU2711512C2 (ru) 2020-01-17
MX365331B (es) 2019-05-29
HUE038915T2 (hu) 2018-12-28
EP2945651B1 (en) 2018-03-07
ZA201503282B (en) 2016-11-30
US20210162034A1 (en) 2021-06-03
BR112015014991A8 (pt) 2023-04-25
CN105120896B (zh) 2019-11-12
IL273685B1 (en) 2023-06-01
CA2895327C (en) 2021-06-01
CA2895327A1 (en) 2014-07-24
DK2945651T3 (en) 2018-06-14
AU2014206799B9 (en) 2018-05-10
US20170087236A1 (en) 2017-03-30
TR201807924T4 (tr) 2018-06-21
BR112015014991A2 (pt) 2017-07-11
IL273685A (en) 2020-05-31
WO2014111516A1 (en) 2014-07-24
JP2019068842A (ja) 2019-05-09
IL239370A0 (en) 2015-07-30
AU2018204437A1 (en) 2018-07-12
JP2016511633A (ja) 2016-04-21
AU2018204437B2 (en) 2019-04-04
AU2014206799A1 (en) 2015-05-21
IL273685B2 (en) 2023-10-01
JP2019068841A (ja) 2019-05-09
MX2015008653A (es) 2016-02-05
US20230277643A1 (en) 2023-09-07
EP2945651A1 (en) 2015-11-25
ES2669420T3 (es) 2018-05-25
BR112015014991B1 (pt) 2024-01-23
NZ707777A (en) 2019-12-20
US10940191B2 (en) 2021-03-09
US20150322138A1 (en) 2015-11-12
IL239370B (en) 2020-04-30
US11529405B2 (en) 2022-12-20
JP6553517B2 (ja) 2019-07-31
CN105120896A (zh) 2015-12-02
ES2718051T3 (es) 2019-06-27
US9849169B2 (en) 2017-12-26
PL2945651T3 (pl) 2018-08-31
PT2945651T (pt) 2018-06-12
AU2014206799B2 (en) 2018-04-19
RU2015134413A (ru) 2017-02-21
EP3167903B1 (en) 2018-12-26
US10206992B2 (en) 2019-02-19
EP3167903A1 (en) 2017-05-17
US20190111121A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
NZ707777A (en) Mdr e. coli specific antibody
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
TN2014000438A1 (en) Anti-fcrn antibodies
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
TN2015000396A1 (en) Antibody drug conjugates
WO2014172046A3 (en) Gene fusions and gene variants associated with cancer
WO2015112626A8 (en) Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AR091098A1 (es) ANTICUERPOS E INMUNOCONJUGADOS CONTRA Ly6E Y METODOS DE USO
WO2014163714A3 (en) Antibody drug conjugates
NZ700578A (en) Cross-reactive staphylococcus aureus antibody
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
PH12014502855B1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
PH12016500753B1 (en) Antibodies specific to fcrn
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX366112B (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
BR112015003032A8 (pt) anticorpos isolados,ácidos nucleico isolados,célula hospedeira,método de produzir um anticorpo,imunoconjugado,formulação famacêutica,uso do anticorpo e método de tratamento de um indivíduo.
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
EP2928492A4 (en) Hiv-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies
IN2015DN02772A (es)
WO2016054053A3 (en) Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
PL401502A1 (pl) Epitop i jego zastosowanie
BR112015029009A2 (pt) Anticorpos, ácido nucleico, célula hospedeira, método de produção de anticorpo, formulação farmacêutica e usos de um anticorpo